New strategies for the treatment of Parkinson's disease hold considerable promise for the future management of neurodegenerative disorders
暂无分享,去创建一个
Carsten R. Bjarkam | C. Bjarkam | K. Østergaard | N. Sunde | Karen Østergaard | Jens Chr. Sørensen | Niels Å. Sunde | Finn A. Geneser | J. Sørensen | F. Geneser
[1] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[2] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[3] Sanford P. Markey,et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.
[4] J. Dostrovsky,et al. Methods for microelectrode-guided posteroventral pallidotomy. , 1996, Journal of neurosurgery.
[5] C. Marsden,et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. , 2000, Brain : a journal of neurology.
[6] H. Widner. The case for neural tissue transplantation as a treatment for Parkinson's disease. , 1999, Advances in neurology.
[7] L. Hansson,et al. Long‐term intraduodenal infusion of a water based levodopa‐carbidopa dispersion in very advanced Parkinson's disease , 1998, Acta neurologica Scandinavica.
[8] S. Aquilonius,et al. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease , 2004, European Journal of Clinical Pharmacology.
[9] C. Olanow,et al. Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.
[10] G. E. Alexander,et al. Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.
[11] Å. Bertler,et al. Occurrence and distribution of catechol amines in brain. , 1959, Acta physiologica Scandinavica.
[12] C. Rebert,et al. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.
[13] D. Jacobowitz,et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[14] C. Economo. Die Encephalitis lethargica , 1918 .
[15] J. O. Dostrovsky,et al. Thalamotomy for Parkinson’s Disease: Microelectrode Technique , 1988 .
[16] J. Obeso,et al. Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.
[17] B. Lippitz,et al. Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. , 1994, Neurosurgery.
[18] A. Benabid,et al. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. , 1987, Applied neurophysiology.
[19] E. Spiegel,et al. Ansotomy in paralysis agitans. , 1954, A.M.A. archives of neurology and psychiatry.
[20] G. Meco,et al. Familial Parkinson’s Disease: A Clinical Genetic Analysis , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[21] L. Forno,et al. Neuropathology of Parkinson's Disease , 1996, Journal of neuropathology and experimental neurology.
[22] C. Clough,et al. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. , 1991, Archives of neurology.
[23] R. Duvoisin,et al. ENCEPHALITIS AND PARKINSONISM. , 1965, Archives of neurology.
[24] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[25] J. Trojanowski,et al. Neuropathology of synuclein aggregates , 2000, Journal of neuroscience research.
[26] A. Carlsson,et al. The occurrence, distribution and physiological role of catecholamines in the nervous system. , 1959, Pharmacological reviews.
[27] J. Nutt,et al. Increased risk of Parkinson's disease in parents and siblings of patients , 1994, Annals of neurology.
[28] C. Tanner. Epidemiology of Parkinson’s Disease , 1992, Neurologic Clinics.
[29] D. Guehl,et al. High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases. , 1997, Journal of neurosurgery.
[30] H. Przuntek,et al. Effect of selegiline on mortality in patients with Parkinson's disease , 1998, Neurology.
[31] A. Bjo¨rklund,et al. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants , 1979, Brain Research.
[32] C. Camp. PATHOLOGY OF PARALYSIS AGITANS. , 1907 .
[33] A. Björklund,et al. Generation of DOPA-Producing Astrocytes by Retroviral Transduction of the Human Tyrosine Hydroxylase Gene:In VitroCharacterization andin VivoEffects in the Rat Parkinson Model , 1996, Experimental Neurology.
[34] J. Langston,et al. Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.
[35] J. Speelman,et al. O-18-264 Thalamic stimulation versus thalamotomy in a prospective randomized trial , 1997, Clinical Neurology and Neurosurgery.
[36] J. Obeso,et al. Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification , 1992, Movement disorders : official journal of the Movement Disorder Society.
[37] J. Dostrovsky,et al. Effect of GPi pallidotomy on motor function in Parkinson's disease , 1995, The Lancet.
[38] André Parent,et al. Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity , 1988, Brain Research.
[39] A. Benabid,et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus , 1991, The Lancet.
[40] M. Hariz. Current controversies in pallidal surgery. , 1999, Advances in neurology.
[41] I. Cooper,et al. Surgical treatment of parkinsonism. , 1961, British medical journal.
[42] R. Duvoisin. Genetic and environmental factors in Parkinson's disease. , 1999, Advances in neurology.
[43] J. Dostrovsky,et al. Deep brain stimulation and thalamotomy for tremor compared. , 1997, Acta neurochirurgica. Supplement.
[44] B. Snow,et al. The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled Study , 2000, Clinical neuropharmacology.
[45] I. Ziv,et al. Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis. , 1999, Advances in neurology.
[46] Scott T. Grafton,et al. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. , 1990, Archives of neurology.
[47] A. Parent,et al. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop , 1995, Brain Research Reviews.
[48] A. Dagher,et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. , 2000, Journal of neurosurgery.
[49] A. Björklund,et al. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. , 1996, Neuroscience.
[50] H. Bergman,et al. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.
[51] J. Greenfield,et al. THE BRAIN-STEM LESIONS IN PARKINSONISM , 1953, Journal of neurology, neurosurgery, and psychiatry.
[52] Richard S. J. Frackowiak,et al. Impaired mesial frontal and putamen activation in Parkinson's disease: A positron emission tomography study , 1992, Annals of neurology.
[53] S. Mandel,et al. Apomorphine protects against MPTP‐induced neurotoxicity in mice , 1999, Movement disorders : official journal of the Movement Disorder Society.
[54] G. E. Alexander. Basal Ganglia‐Thalamocortical Circuits: Their Role in Control of Movements , 1994, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.
[55] D. Brooks,et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.
[56] J. A. Obeso,et al. Restoration of thalamocortical activity after posteroventral pallidotomy in Parkinson's disease , 1994, The Lancet.
[57] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[58] M. Youdim,et al. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6‐Hydroxydopamine , 1998, Movement disorders : official journal of the Movement Disorder Society.
[59] A J Lees,et al. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.
[60] E. Love,et al. Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.
[61] A. Björklund,et al. Immortalized neural progenitor cells for CNS gene transfer and repair , 1997, Trends in Neurosciences.
[62] L. J. Fisher,et al. In vivo and ex vivo gene transfer to the brain , 1994, Current Opinion in Neurobiology.
[63] R. Turner,et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1‐year results of a pilot study , 1996, Annals of neurology.
[64] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[65] P R Sanberg,et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.
[66] V. Kostic,et al. Early development of levodopa‐induced dyskinesias and response fluctuations in young‐onset Parkinson's disease , 1991, Neurology.
[67] W Fernandez,et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine , 1992, Annals of neurology.
[68] J. Parkinson. An Essay on the Shaking Palsy , 2002 .
[69] M. Hariz,et al. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. , 1992, Journal of neurosurgery.
[70] B J Hoffer,et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. , 1989, Archives of neurology.
[71] T. Deacon,et al. Xenotransplantation of Porcine Fetal Ventral Mesencephalon in a Rat Model of Parkinson's Disease: Functional Recovery and Graft Morphology , 1996, Experimental Neurology.
[72] C. Marsden,et al. A clinical and genetic study of familial Parkinson's disease , 1991, Movement disorders : official journal of the Movement Disorder Society.
[73] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[74] A. Lang,et al. Posteroventral medial pallidotomy in advanced Parkinson's disease. , 1997, New England Journal of Medicine.
[75] J. Yelnik. Functional anatomy of the basal ganglia , 2002, Movement disorders : official journal of the Movement Disorder Society.
[76] A L Benabid,et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. , 1998, Brain : a journal of neurology.
[77] S. Kuniyoshi,et al. Electrophysiologic target localization in posteroventral pallidotomy , 2005, Acta Neurochirurgica.
[78] A. Lang,et al. Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.
[79] A. Benabid,et al. Opposite motor effects of pallidal stimulation in Parkinson's disease , 1998, Annals of neurology.
[80] S. Horai,et al. Is Parkinson's disease a mitochondrial disorder? , 1992, Journal of the Neurological Sciences.
[81] L. Golbe,et al. A clinical genetic study of Parkinson's disease , 1994, Neurology.
[82] J. Jankovic,et al. Surgical treatment of levodopa-induced dyskinesias. , 1999, Advances in neurology.
[83] S. Dunnett. Transplantation of embryonic dopamine neurons: what we know from rats , 1991, Journal of Neurology.
[84] S. Roy,et al. Parkinson's disease in a Scottish city. , 1986, British medical journal.
[85] S. Rietbrock,et al. Concentration-Effect Relationship of Levodopa in Patients with Parkinson’s Disease , 1995, Clinical pharmacokinetics.
[86] M. Chesselet,et al. Basal ganglia and movement disorders: an update , 1996, Trends in Neurosciences.
[87] E Kanal,et al. A comparison between magnetic resonance imaging and computed tomography for stereotactic coordinate determination. , 1992, Neurosurgery.
[88] Ole Isacson,et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease , 1997, Nature Medicine.
[89] J. Guieu,et al. Control of tremor and involuntary movement disorders by chronic stereotactic stimulation of the ventral intermediate thalamic nucleus. , 1992, Journal of neurosurgery.
[90] S. Aquilonius,et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease , 2004, European Journal of Clinical Pharmacology.
[91] C. Tanner,et al. The role of environmental toxins in the etiology of Parkinson's disease , 1989, Trends in Neurosciences.
[92] Richard S. J. Frackowiak,et al. Evidence for long‐term survival and function of dopaminergic grafts in progressive Parkinson's disease , 1994, Annals of neurology.
[93] J. Nutt. On‐off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics , 1987, Annals of neurology.
[94] P. Brundin,et al. Lazaroids improve the survival of grafted rat embryonic dopamine neurons. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[95] S. Wiegand,et al. BDNF Enhances the Functional Reinnervation of the Striatum by Grafted Fetal Dopamine Neurons , 1996, Experimental Neurology.
[96] Patrik Brundin,et al. Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis , 1988, Brain Research Reviews.
[97] G K Wenning,et al. Apomorphine: An underutilized therapy for Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[98] A. Lees,et al. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease , 1995, BMJ.
[99] A. Parent,et al. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidium in basal ganglia circuitry , 1995, Brain Research Reviews.
[100] J. Larsen,et al. Does selegiline modify the progression of early Parkinson's disease? Results from a five‐year study , 1999, European journal of neurology.
[101] O. Lindvall. Neural transplantation: can we improve the symptomatic relief? , 1999, Advances in neurology.
[102] M. Merello,et al. [Functional anatomy of the basal ganglia]. , 2000, Revista de neurologia.
[103] D. Perl,et al. Projected neurodegenerative disease mortality in the United States, 1990-2040. , 1993, Neuroepidemiology.
[104] D. Maraganore. Epidemiology and Genetics of Parkinson’s Disease , 2000 .
[105] A. Benabid,et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. , 1996, Journal of neurosurgery.
[106] L. Leksell,et al. TREATMENT OF PARKINSONISM BY STEREOTACTIC THERMOLESIONS IN THE PALLIDAL REGION. A clinical evaluation of 81 cases. , 1960, Acta psychiatrica Scandinavica.
[107] S. Fahn,et al. Selegiline and mortality in Parkinson's disease , 1996, Annals of neurology.
[108] A. Carlsson,et al. On the presence of 3-hydroxytyramine in brain. , 1958, Science.
[109] A. Benabid,et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation , 1995, The Lancet.
[110] G. Boer,et al. Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research , 1994, Journal of Neurology.
[111] K. Jellinger,et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.
[112] A. Björklund,et al. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release , 1988, Experimental Brain Research.
[113] L. Descarries,et al. Distribution of GABA‐immunoreactive neurons in the basal ganglia of the squirrel monkey (Saimiri sciureus) , 1987, The Journal of comparative neurology.
[114] Ornella Rimoldi,et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient , 1999, Nature Neuroscience.
[115] S. Konitsiotis,et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. , 1999, Archives of neurology.
[116] G. Selby. Stereotactic surgery for the relief of Parkinson's disease , 1967 .
[117] D. Spencer,et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. , 1992, The New England journal of medicine.
[118] F. J. Gillingham,et al. The long-term results of stereotaxic surgery and L-dopa therapy in patients with Parkinson's disease. A 10-year follow-up study. , 1980, Journal of neurosurgery.
[119] G. Wooten,et al. Maternal inheritance in Parkinson's disease , 1997, Annals of neurology.
[120] O. Lindvall. Clinical application of neuronal grafts in Parkinson's disease , 1994, Journal of Neurology.
[121] Robert Hill,et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.
[122] C. Gerfen. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. , 1992, Annual review of neuroscience.
[123] C. C. Johnson,et al. Parkinson's disease mortality and the industrial use of heavy metals in Michigan , 1993, Movement disorders : official journal of the Movement Disorder Society.
[124] W. Freed. Substantia nigra grafts and Parkinson's disease: from animal experiments to human therapeutic trials. , 1991, Restorative neurology and neuroscience.
[125] Richard S. J. Frackowiak,et al. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease , 1997, Annals of neurology.
[126] K. Planansky. Paralysis agitans: A clinical and genetic study , 1950 .
[127] S. Fahn,et al. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.